Article
Cerivastatin, genetic variants, and the risk of rhabdomyolysis.
Pharmacogenetics and genomics - 1 May 2011
Marciante Kristin D, Durda Jon P, Heckbert Susan R, Lumley Thomas, Rice Ken, McKnight Barbara, Totah Rheem A, Tamraz Bani, Kroetz Deanna L, Fukushima Hisayo, Kaspera Rüdiger, Bis Joshua C, Glazer Nicole L, Li Guo, Austin Thomas R, Taylor Kent D, Rotter Jerome I, Jaquish Cashell E, Kwok Pui-Yan, Tracy Russell P, Psaty Bruce M
Abstract excerpt
OBJECTIVE: The withdrawal of cerivastatin involved an uncommon but serious adverse reaction, rhabdomyolysis. The bimodal response, rhabdomyolysis in a small proportion of users, points to genetic factors as a potential cause. We conducted a case-control study to evaluate genetic markers for cerivastatin-associated rhabdomyolysis. METHODS: This study had two components: a candidate gene study to evaluate variants...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.